Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Quest Diagnostics Inc — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.7, while Quest Diagnostics Inc trades at $205.45 (market cap $22.80B). The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | DGX | |
|---|---|---|
52-Week High | $75.17 | $216.02 |
52-Week Low | $72.45 | $166.42 |
Market Cap | — | $22.80B |
Sector | — | Health |
Enterprise Value | — | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.50, down 0.37% with a bearish technical outlook showing 19 sell signals versus 4 buy signals. The ETF faces pressure from rising interest rate expectations, though recent dividend payments of $0.24-$0.25 provide income stability. Fixed income ETFs have seen renewed investor interest with $100 billion flowing into cash ETFs recently, indicating defensive positioning.
The bond ETF faces headwinds from potential Fed rate hikes but offers diversification benefits. Key risks include interest rate sensitivity and competition from higher-yielding alternatives. Long-term investors may find value in BND's broad market exposure and low costs despite near-term technical weakness.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
